[go: up one dir, main page]

DE69940964D1 - Methods and compositions for inhibiting neoplastic cell growth - Google Patents

Methods and compositions for inhibiting neoplastic cell growth

Info

Publication number
DE69940964D1
DE69940964D1 DE69940964T DE69940964T DE69940964D1 DE 69940964 D1 DE69940964 D1 DE 69940964D1 DE 69940964 T DE69940964 T DE 69940964T DE 69940964 T DE69940964 T DE 69940964T DE 69940964 D1 DE69940964 D1 DE 69940964D1
Authority
DE
Germany
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940964T
Other languages
German (de)
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Scot A Marsters
Mary A Napier
Robert M Pitti
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69940964D1 publication Critical patent/DE69940964D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
DE69940964T 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth Expired - Lifetime DE69940964D1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US13023299P 1999-04-21 1999-04-21
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
DE69940964D1 true DE69940964D1 (en) 2009-07-16

Family

ID=27557838

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69935085T Expired - Lifetime DE69935085T2 (en) 1998-12-22 1999-12-02 Method and composition for inhibiting neoplastic cell growth
DE69940964T Expired - Lifetime DE69940964D1 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69935085T Expired - Lifetime DE69935085T2 (en) 1998-12-22 1999-12-02 Method and composition for inhibiting neoplastic cell growth

Country Status (13)

Country Link
EP (1) EP1141284A2 (en)
JP (5) JP3993746B2 (en)
KR (1) KR100499600B1 (en)
AT (2) ATE432987T1 (en)
AU (1) AU768230B2 (en)
CA (1) CA2353799A1 (en)
DE (2) DE69935085T2 (en)
DK (1) DK1484338T3 (en)
ES (2) ES2281704T3 (en)
IL (3) IL143031A0 (en)
MX (1) MXPA01006330A (en)
PT (1) PT1484338E (en)
WO (1) WO2000037638A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
JP2002504308A (en) 1997-11-22 2002-02-12 ハイセック インコーポレイテッド Novel EGF motif protein obtained from fetal liver-spleen cDNA library
EP1251139A3 (en) * 1998-04-08 2002-12-18 Genentech, Inc. Human mindin-like protein and nucleic acids encoding it
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AU768694B2 (en) * 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU4011300A (en) * 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
MXPA02005758A (en) * 1999-12-09 2002-09-18 Sankyo Co Method of testing remedy or preventive for hyperlipemia.
PL356887A1 (en) * 2000-01-12 2004-07-12 Yale University Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
DE60141409D1 (en) 2000-10-06 2010-04-08 Biogen Idec Inc HOMOLOGO OF NOGO RECEPTOR
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
SI1997512T1 (en) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS OF SUPPRESSING AXONAL GROWTH INHIBITION
ES2551202T5 (en) 2005-11-04 2018-11-30 Genentech, Inc. Use of complement pathway inhibitors to treat eye diseases
EP2010226B1 (en) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CN106084054A (en) 2006-11-02 2016-11-09 健泰科生物技术公司 Humanized anti-D factor antibody
AR066660A1 (en) 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
LT2280996T (en) 2008-05-06 2016-12-12 Genentech, Inc. AFFINITY MATURED CRIg VARIANTS
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CR20160132A (en) 2013-08-12 2016-08-25 Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN114835774B (en) * 2022-06-29 2022-09-27 中国农业大学 Oligopeptide MSL separated from pepper seeds and application thereof in preventing or treating cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (en) * 1998-06-02 2000-04-11 Lilly Co Eli ANGIOPOYETIN RELATED TO SEQUENCE OF GEN 3 IN FACE SCAR REF. X-12261
JP7039446B2 (en) * 2018-11-29 2022-03-22 株式会社東芝 Electronic device

Also Published As

Publication number Publication date
EP1141284A2 (en) 2001-10-10
DK1484338T3 (en) 2007-06-11
JP2007291116A (en) 2007-11-08
JP2005237383A (en) 2005-09-08
IL186153A0 (en) 2008-01-20
JP2005245451A (en) 2005-09-15
ATE432987T1 (en) 2009-06-15
ES2327785T3 (en) 2009-11-03
DE69935085D1 (en) 2007-03-22
CA2353799A1 (en) 2000-06-29
KR20010084882A (en) 2001-09-06
KR100499600B1 (en) 2005-07-07
PT1484338E (en) 2007-05-31
JP3993746B2 (en) 2007-10-17
ES2281704T3 (en) 2007-10-01
IL143031A0 (en) 2002-04-21
WO2000037638A3 (en) 2000-11-09
ATE353339T1 (en) 2007-02-15
JP4037876B2 (en) 2008-01-23
JP2003529317A (en) 2003-10-07
AU1749900A (en) 2000-07-12
AU768230B2 (en) 2003-12-04
DE69935085T2 (en) 2007-08-23
WO2000037638A2 (en) 2000-06-29
MXPA01006330A (en) 2002-07-02
JP2007222180A (en) 2007-09-06
IL186154A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
ATE432987T1 (en) METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH
ATE357518T1 (en) METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH
ATE408419T1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR
ATE380195T1 (en) COMPOSITIONS AND METHODS FOR TREATING TUMORS
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
WO2002026822A3 (en) Pumpcn compositions and uses thereof
ATE397063T1 (en) FIBROBLAST GROWTH FACTOR-19
ATE444971T1 (en) COMPOSITIONS AND METHODS FOR TUMOR TREATMENT
ATE439431T1 (en) COMPOSITION AND METHOD FOR DIAGNOSIS OF TUMORS
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP2075335A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820860A3 (en) Methods and compositions for inhibiting neoplastic cell growth
KR100515858B1 (en) PRO617 Polypeptides
WO2000007545A3 (en) Apoptosis proteins
KR100515857B1 (en) PRO792 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
KR100515856B1 (en) PRO618 Polypeptides
DK1249491T3 (en) Nucleic acid that is propagated in human tumors as well as related materials and methods

Legal Events

Date Code Title Description
8364 No opposition during term of opposition